Literature DB >> 18282014

Projecting vaccine efficacy: accounting for geographic strain variations.

Johnie Rose1, Mendel E Singer.   

Abstract

Researchers must often make assumptions about the efficacy of an intervention in a target population without the benefit of trial data specific to that population. Such assumptions may be particularly tenuous with models of vaccination strategies, since the distribution of pathogen strains in target populations may differ substantially from the strain distributions in trial sites. We describe a technique for projecting expected vaccine efficacy in settings where applying unadjusted trial-based efficacy data may overestimate the benefits of immunization. This simple method uses data describing setting-specific strain distributions of pathogens and strain-specific vaccine efficacies to generate a weighted overall efficacy. An example of estimating the expected efficacy of a new rotavirus vaccine in India is used to illustrate the technique. The method is shown to perform very well in a validation population for whom actual efficacy had been observed and can therefore aid those in the international health community in determining the optimal uses of scarce resources.

Mesh:

Substances:

Year:  2008        PMID: 18282014     DOI: 10.2165/00019053-200826030-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

1.  Great diversity of group A rotavirus strains and high prevalence of mixed rotavirus infections in India.

Authors:  V Jain; B K Das; M K Bhan; R I Glass; J R Gentsch
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Authors:  Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

3.  Public health. Progress toward rotavirus vaccines.

Authors:  Umesh D Parashar; Roger I Glass
Journal:  Science       Date:  2006-05-12       Impact factor: 47.728

4.  Rotavirus vaccines: targeting the developing world.

Authors:  Roger I Glass; Joseph S Bresee; Reina Turcios; Thea K Fischer; Umesh D Parashar; A Duncan Steele
Journal:  J Infect Dis       Date:  2005-09-01       Impact factor: 5.226

5.  Projected cost-effectiveness of rotavirus vaccination for children in Asia.

Authors:  Laura Jean Podewils; Lynn Antil; Erik Hummelman; Joseph Bresee; Umesh D Parashar; Richard Rheingans
Journal:  J Infect Dis       Date:  2005-09-01       Impact factor: 5.226

6.  Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

Authors:  Bélen Salinas; Irene Pérez Schael; Alexandre C Linhares; Guillermo M Ruiz Palacios; M Lourdes Guerrero; Juan Pablo Yarzábal; Yolanda Cervantes; SueAnn Costa Clemens; Silvia Damaso; Karin Hardt; Béatrice De Vos
Journal:  Pediatr Infect Dis J       Date:  2005-09       Impact factor: 2.129

7.  Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.

Authors:  M Jit; W J Edmunds
Journal:  Vaccine       Date:  2007-03-13       Impact factor: 3.641

8.  Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

Authors:  Timo Vesikari; Aino Karvonen; Leena Puustinen; Shang-Qin Zeng; Evelyn Dora Szakal; Andrée Delem; Beatrice De Vos
Journal:  Pediatr Infect Dis J       Date:  2004-10       Impact factor: 2.129

Review 9.  Rotavirus vaccines: current prospects and future challenges.

Authors:  Roger I Glass; Umesh D Parashar; Joseph S Bresee; Reina Turcios; Thea K Fischer; Marc-Alain Widdowson; Baoming Jiang; Jon R Gentsch
Journal:  Lancet       Date:  2006-07-22       Impact factor: 79.321

10.  Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.

Authors:  Thea K Fischer; Dang Duc Anh; Lynn Antil; N D L Cat; Paul E Kilgore; Vu D Thiem; Rick Rheingans; Le H Tho; Roger I Glass; Joseph S Bresee
Journal:  J Infect Dis       Date:  2005-10-14       Impact factor: 5.226

View more
  3 in total

1.  Rotavirus genotypes in Malaysia and universal rotavirus vaccination.

Authors:  Way Seah Lee; Benjamin Tze Ying Lim; Pei Fan Chai; Carl D Kirkwood; Jimmy Kok Foo Lee
Journal:  Hum Vaccin Immunother       Date:  2012-09-28       Impact factor: 3.452

2.  Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries.

Authors:  Antoine C El Khoury; T Christopher Mast; Max Ciarlet; Leona E Markson; Michelle G Goveia
Journal:  Hum Vaccin       Date:  2011-05-01

3.  Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.

Authors:  Johnie Rose; Rachael L Hawthorn; Brook Watts; Mendel E Singer
Journal:  BMJ       Date:  2009-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.